Comparative Pharmacology
Head-to-head clinical analysis: EVOMELA versus NEOSAR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EVOMELA versus NEOSAR.
EVOMELA vs NEOSAR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
EVOMELA (melphalan) is a bifunctional alkylating agent that forms cross-links between DNA strands, inhibiting DNA replication and transcription, leading to cell death.
Alkylating agent that inhibits DNA replication and transcription by cross-linking DNA strands, leading to cell cycle arrest and apoptosis.
140-200 mg/m² IV over 30 minutes for conditioning prior to ASCT; off-label: 16 mg/m² IV over 15-20 minutes every 4 weeks for MM.
Cyclophosphamide 500-1500 mg/m² IV every 2-4 weeks; oral 50-200 mg daily.
None Documented
None Documented
Terminal elimination half-life is approximately 75 minutes (range 40-120 minutes) in patients with normal renal function; prolonged to 180-300 minutes in renal impairment
Terminal elimination half-life: 3-5 hours; prolonged in hepatic impairment (up to 12 hours).
Primarily renal: approximately 10-30% of unchanged drug excreted in urine within 24 hours; extensive hepatic metabolism; fecal excretion accounts for <5%
Renal: 30-60% unchanged; biliary/fecal: 10-20% as metabolites.
Category C
Category C
Alkylating Agent
Alkylating Agent